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Background: Incident hemodialysis patients have the highest mortality in the ﬁrst
several months after starting dialysis. This study evaluated the in-hospital mortality
rate after hemodialysis initiation, as well as related risk factors.
Methods: We examined in-hospital mortality and related factors in 2,692 patients
starting incident hemodialysis. The study population included patients with acute
kidney injury, acute exacerbation of chronic kidney disease, and chronic kidney disease.
To determine the parameters associated with in-hospital mortality, patients who died in
hospital (nonsurvivors) were compared with those who survived (survivors). Risk
factors for in-hospital mortality were determined using logistic regression analysis.
Results: Among all patients, 451 (16.8%) died during hospitalization. The highest risk
factor for in-hospital mortality was cardiopulmonary resuscitation, followed by pneu-
monia, arrhythmia, hematologic malignancy, and acute kidney injury after bleeding.
Albuminwas not a risk factor for in-hospital mortality, whereas C-reactive proteinwas a
risk factor. The use of vancomycin, inotropes, and a ventilator was associated with
mortality, whereas elective hemodialysis with chronic kidney disease and statin use
were associated with survival. The use of continuous renal replacement therapy was not
associated with in-hospital mortality.
Conclusion: Incident hemodialysis patients had high in-hospital mortality. Cardiopul-
monary resuscitation, infections such as pneumonia, and the use of inotropes and a
ventilator was strong risk factors for in-hospital mortality. However, elective hemodia-
lysis for chronic kidney disease was associated with survival.
Copyright & 2015. The Korean Society of Nephrology. Published by Elsevier. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The annual mortality rate of hemodialysis (HD) patients
exceeds 20% [1]. The mortality rate is even higher during the
1st year of dialysis therapy, especially in the 1st few months [1].
However, the risk factors for in-hospital mortality are largely15. The Korean Society of Nep
.org/licenses/by-nc-nd/4.0/).
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m).unknown. Early mortality occurring in the 1st 90 days after
starting renal replacement therapy (RRT) is responsible for a
large proportion of the 1st year mortality rate, which ranges
12.6–32.0% [2]. Short-term prognosis studies report varying
results because of different methodologies [3]. For example,
Canadian studies considered the early period as the 1st 6
months after starting RRT [4,5], whereas others excluded
mortality that occurred in the 1st month [6]. Meanwhile, the
United States Renal Data System registry excludes all patients
who did not survive beyond 90 days and only analyzes
mortality that occurred in patients aged more than 65 years [7].hrology. Published by Elsevier. This is an open access article under the
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cardiovascular disease followed by infectious disease. A recent
study examining early mortality among incident HD patients
during the 1st 120 days versus the subsequent 121–365 days
shows cardiovascular diseases were still the most common
cause of death during the entire 1st year [8].
Although previous studies have identiﬁed several important
factors associated with increased mortality in incident HD
patients, few have addressed the risk factor patterns and their
temporal changes during their 1st few months of dialysis therapy.
It is crucial to determine if these risk patterns remain constant or
change over time, so that targeted interventions can be used at
different periods of time. Therefore, the present study examined
the risk factors for in-hospital mortality after the start of HD
therapy in incident HD patients who had started treatment.Methods
Study population and design
We reviewed the records of 2,692 new patients who started
HD at the Chonnam National University Hospital from January 1,
2007 through December 31, 2011. Patients with acute kidney
injury (AKI), acute exacerbation of chronic kidney disease (CKD),
or CKD with programmed RRT were included.Data collection and deﬁnitions
The following clinical data were collected: age, sex, body
mass index, cause of admission, presence of cardiopulmonary
resuscitation (CPR), comorbidity, ﬁrst mode of HD (i.e., emer-
gency or programmed dialysis), in-hospital medication, vascular
access, dialysis frequency (times per week), and mortality during
hospitalization.Table 1. Comparison for clinical risk factors at starting hemodialysis
Variables Nonsurvivor (n
Age (y) 64.7714.9
Sex (male) 283 (62.7)
Body mass index (kg/m2) 22.973.9
On admission
Via emergency room 360 (79.8)
After cardiac pulmonary resuscitation 94 (20.8)
Comorbidities
Hypertension 237 (52.5)
Diabetes mellitus 176 (39.7)
Cardiovascular disease 63 (14.0)
Hyperlipidemia 10 (2.2)
Solid tumor 87 (19.3)
Heart failure 17 (3.8)
Hematologic malignancy 38 (8.4)
Smoking 161 (35.7)
Cause of admission
Chronic kidney disease 149 (33.0)
Urinary tract infection 9 (2.0)
Pneumonia 78 (17.3)
Acute myocardial infarction 31 (6.9)
Postchemotherapy 27 (6.0)
Postbleeding 107 (23.7)
Stone 10 (2.2)
Postoperation 17 (3.8)
Others 23 (5.1)
Data are presented as mean 7 SD or n (%).The following laboratory parameters were recorded at
admission and when starting HD: blood gas analysis parameters
such as PaO2 and HCO3; blood parameters such as white blood
cell count, hemoglobin, blood urea nitrogen, creatinine, aspartate
aminotransferase, alanine aminotransferase, total bilirubin, direct
bilirubin, sodium, potassium, calcium, phosphorus, albumin,
C-reactive protein (CRP), and low-density lipoprotein cholesterol;
and urinalysis parameters such as proteinuria (430 mg/g
creatinine) and hematuria (red blood cells 43/high power ﬁeld).
Statistical analyses
To determine the parameters associated with in-hospital
mortality, patients who died in hospital (nonsurvivors) were
compared with those who survived (survivors). All continuous
variables are presented as mean7standard deviation. For
univariate analysis, categorical and continuous variables were
analyzed with the χ2 test and Student t test, respectively.
Variables associated with in-hospital mortality showing P o
0.25 in univariate analysis were entered into multivariate
stepwise logistic regression analysis. Adjusted hazard ratios
(aHRs) and 95% conﬁdence intervals (CIs) were calculated. All
analyses were two tailed, and the level of signiﬁcance was set
at P o 0.05. All analyses were performed using SPSS, version
18.0, for Windows (SPSS Inc., Chicago, IL, USA).Results
The clinical parameters of the study patients are summar-
ized in Table 1. Of 2,692 patients, 451 (16.8%) died during
hospitalization after starting incident HD. Survivors were
younger than nonsurvivors (60.2714.6 years vs. 64.7714.9
years, P o 0.001). Sex and body mass index did not differ
between nonsurvivors and survivors. The prevalence of dia-
betes mellitus was higher in survivors, whereas the prevalence
of solid tumors, hematologic malignancy, and smoking was¼451) Survivor (n¼2,241) P
60.2714.6 <0.001
1,367 (61.0) 0.492
23.276.4 0.412
1,644 (73.4) 0.004
16 (0.7) <0.001
1,630 (72.7) 0.246
1,116 (49.8) <0.001
335 (14.9) 0.663
56 (2.5) 0.868
237 (10.6) <0.001
79 (3.5) 0.876
34 (1.5) <0.001
665 (29.7) 0.035
1,565 (69.8) <0.001
27 (1.2) 0.180
112 (5.0) <0.001
83 (3.7) 0.004
31 (1.7) <0.001
218 (9.7) <0.001
35 (1.6) 0.315
58 (2.6) 0.160
112 (5.0) 0.612
Table 2. Laboratory ﬁndings at admission
Variables Nonsurvivor (n¼451) Survivor (n¼2,241) P
PaO2 (mmHg) 96.7759.2 86.5749.2 <0.001
HCO3 (mmol/L) 18.376.8 18.376.8 0.930
White blood cell (103/mm3) 14.0717.2 9.977.5 <0.001
Hemoglobin (g/dL) 10.672.6 9.973.2 <0.001
AST (U/L) 240.471,760.7 106.97914.0 0.118
ALT (U/L) 97.37371.7 59.17326.2 0.043
Total bilirubin (mg/dL) 1.673.6 0.971.5 <0.001
Direct bilirubin (mg/dL) 1.271.8 0.872.2 0.017
Albumin (g/dL) 3.171.2 3.471.1 <0.001
Blood urea nitrogen (mg/dL) 47.1735.5 71.4748.5 <0.001
Creatinine (mg/dL) 3.473.0 7.876.0 <0.001
Sodium (mEq/L) 135.277.9 134.878.4 0.333
Potasssium (mEq/L) 4.571.1 5.574.7 0.087
PT (INR) 1.470.8 1.370.5 0.338
Lactate dehydrogenase (U/L) 1,311.273,036.7 704.771,430.0 <0.001
C-reactive protein (mg/dL) 9.579.5 5.6717.6 <0.001
Inorganic phosphate (mg/dL) 4.772.3 5.6715.5 0.214
Total calcium (mg/dL) 7.272.0 7.172.6 0.258
Low-density lipoprotein (mg/dL) 84.6745.7 97.4740.9 0.003
Proteinuria 295 (65.4) 1,615 (72.1) <0.001
Hematuria 383 (84.9) 1,734 (77.3) 0.263
Data are presented as mean 7 SD or n (%).
AST, aspartate transaminase; ALT, alanine transaminase; INR, international normalized ratio; PT, prothrombin time.
Table 3. Laboratory ﬁndings at initial hemodialysis
Variables Nonsurvivor (n¼451) Survivor (n¼2,241) P
PaO2 (mmHg) 95.3742.1 86.9755.3 <0.001
HCO3 (mmol/L) 17.476.9 18.377.0 0.006
White blood cell (103/mm3) 13.9710.8 9.776.2 <0.001
Hemoglobin (g/dL) 10.072.1 9.773.0 0.015
AST (U/L) 485.772,268.1 130.07997.0 0.001
ALT (U/L) 205.07736.0 69.57388.2 <0.001
Total bilirubin (mg/dL) 2.474.3 1.073.0 <0.001
Direct bilirubin (mg/dL) 1.972.7 1.8725.9 0.933
Albumin (g/dL) 2.971.1 3.371.0 <0.001
Blood urea nitrogen (mg/dL) 71.2745.9 81.17198.1 0.289
Creatinine (mg/dL) 4.572.8 8.276.2 <0.001
Sodium (mEq/L) 138.077.7 135.477.7 <0.001
Potassium (mEq/L) 4.771.1 5.371.7 0.255
Data are presented as mean 7 SD or n (%).
ALT, alanine transaminase; AST, aspartate transaminase.
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was more common among survivors, whereas pneumonia,
acute myocardial infarction, chemotherapy, and bleeding were
more common among nonsurvivors.
The laboratory ﬁndings at admission are shown in Table 2.
Compared with survivors, nonsurvivors had a signiﬁcantly
higher white blood cell count and CRP level, as well as lower
albumin and serum creatinine levels. The laboratory ﬁndings
at the start of HD are shown in Table 3. Metabolic acidosis,
hypoxia, leukocytosis, and liver function test results were
worse in nonsurvivors, whereas hemoglobin, serum albumin,
and creatinine levels were lower in nonsurvivors.
Details on in-hospital medications, clinical assistive devices,
and vascular access are shown in Table 4. The use of loop
diuretics, inotropes, vancomycin, and steroids was more com-
mon in nonsurvivors. Meanwhile, the use of angiotensin-
converting enzyme inhibitors, angiotensin II receptor blockers,
statins, calcium channel blockers, and anticoagulants was
more common in survivors. The rate and duration of intensive
care unit (ICU) care, use of continuous RRT, and ventilator
treatment were more common in nonsurvivors. Vascularaccess via the femoral vein was more common in nonsurvi-
vors, whereas access via a tunneled cuffed catheter and
arteriovenous access, including arteriovenous ﬁstula and arter-
iovenous graft, were more common in survivors.
The results of the multivariate analysis of risk factors for in-
hospital mortality in incident HD patients are shown in
Table 5. The presence of CPR was the strongest risk factor for
in-hospital mortality, with an aHR of 31.47 (95% CI: 5.766–
171.814), followed by pneumonia (aHR: 6.408; 95% CI: 2.007–
20.454), solid tumor (aHR: 4.171; 95% CI: 1.333–13.023),
inotrope use (aHR: 11.846; 95% CI: 3.650–38.440), ventilator
use (aHR: 7.561; 95% CI: 2.142–26.686), ICU care (aHR: 6.021;
95% CI: 2.093–17.316), and vancomycin administration (aHR:
2.563; 95% CI: 1.140–5.762). Meanwhile, statin administration
decreased the risk of in-hospital mortality after adjusting for
clinical and biochemical parameters (aHR: 0.199; 95% CI:
0.065–0.610).
The risk factors for in-hospital mortality after excluding
CPR, inotrope administration, ventilator use, ICU care, and
vancomycin are shown in Table 6. Arrhythmia (aHR: 3.253;
95% CI: 2.179–4.856), hematologic malignancy (aHR: 2.088;
Table 4. Comparison for risk factors associated with medication and dialysis modality
Variables Nonsurvivor (n ¼ 451) Survivor (n ¼ 2,241) P
Hemodialysis (h/wk) 8.475.4 9.473.7 <0.001
In-hospital medication
Loop diuretics 381 (84.5) 1,374 (61.3) <0.001
Inotropics 394 (87.4) 860 (38.4) <0.001
ACEI 62 (13.7) 456 (20.3) <0.001
ARB 97 (21.5) 1,040 (46.4) <0.001
Statin 31 (6.9) 449 (20.0) <0.001
CCB 166 (36.8) 1,328 (59.3) <0.001
Vancomycin 176 (39) 296 (13.2) <0.001
Steroid 123 (27.3) 290 (12.9) <0.001
Anticoagulation 145 (32.2) 1,142 (51.0) <0.001
ICU care 354 (78.5) 433 (19.3) <0.001
ICU duration (d) 18.1726.0 13.4716.2 0.003
CRRT 110 (24.4) 75 (3.3) <0.001
CRRT duration (d) 10 (2.2) 56 (2.5) 0.541
Ventilator 310 (68.7) 216 (9.6) <0.001
Access
Femoral venous 289 (64.1) 644 (28.8) <0.001
Temporary jugular venous 43 (9.5) 243 (10.8) 0.451
Jugular venous, tunneled cuffed jugular catheter 77 (17.1) 576 (25.7) <0.001
Arteriovenous ﬁstula or graft 42 (9.3) 778 (34.7) <0.001
Data are presented as mean 7 SD or n (%).
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CRRT, continuous renal
replacement therapy; ICU, intensive care unit.
Table 5. Multivariate analysis for risk factors for in-hospital mortality
Variables Adjusted hazard ratio CI P
Age (y) 1.031 0.264–4.025 0.966
Sex (male) 0.812 0.311–2.121 0.671
Body mass index (kg/m2) 0.589 0.148–2.348 0.453
Via emergency room 2.157 0.868–5.357 0.098
After cardiac pulmonary resuscitation 31.474 5.766–171.814 <0.001
Hypertension 0.835 0.326–2.141 0.708
Diabetes mellitus 1.727 0.696–4.288 0.239
Solid tumor 4.171 1.333–13.023 0.014
Pneumonia 6.408 2.007–20.454 0.002
Albumin on HD 0.545 0.279–1.065 0.074
Inotropics 11.846 3.650–38.440 <0.001
Statin 0.199 0.065–0.610 0.005
Vancomycin 2.563 1.140–5.762 0.023
Intensive care unit 6.021 2.093–17.316 0.001
Ventilator 7.561 2.142–26.686 0.002
CRRT 0.597 0.168–2.1138 0.423
Data are presented as mean 7 SD or n (%).
CI, conﬁdence interval; CRRT, continuous renal replacement therapy; HD, hemodialysis.
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5.364), postbleeding (aHR: 2.569; 95% CI: 1.680–3.928), other
infections (aHR: 1.525; 95% CI: 1.068–2.176), and CRP (aHR:
1.011; 95% CI: 1.001–1.021) were signiﬁcant risk factors for in-
hospital mortality, whereas programmed HD for CKD signiﬁ-
cantly decreased the risk of in-hospital mortality (aHR: 0.424;
95% CI: 0.279–0.643).Discussion
In the present study, the in-hospital mortality rate of
patients starting incident HD was 16.8%, which is similar to
that in previous studies, ranging 11–26% [3,5,9–11]; this
variation is likely due to different methodologies used in data
collection and analysis. Several studies report that both all-
cause and cardiovascular-related mortality rates are highestduring the 1st 2 months of dialysis therapy [11,12]. However,
CPR was the strongest risk factor in the present study; the
reason might be study population, which included patients
with AKI of various causes. Previous studies have focused on
evaluating the risk factors for CKD [8,13]. However, this
population-based study focused on patients receiving incident
HD, including not only those with CKD but also those with AKI.
A study of the UK Renal National Registry cohort, including
patients receiving HD and peritoneal dialysis, that used several
models to predict the 3-year survival of incident dialysis
patients reports older age, Caucasian ethnicity, diabetes melli-
tus and other primary causes of end-stage renal disease,
history of cardiovascular disease, and smoking as risk factors
for increased mortality [13].
In the present study, early mortality did not differ signiﬁcantly
between sexes. Some studies report a lower risk of mortality in
women in 1-year survival analyses [12]. Older age, solid tumor,
Table 6. Multivariate analysis for risk factors of in-hospital
mortality
Variables Adjusted
hazard ratio
CI P
Age (y) 1.004 0.992–1.015 0.548
Sex (male) 0.949 0.680–1.325 0.760
Body mass index (kg/m2) 0.990 0.948–1.033 0.635
Hypertension 0.809 0.560–1.168 0.258
Diabetes mellitus 1.057 0.738–1.513 0.764
Solitary tumor 1.340 0.834–2.155 0.227
Arrhythmia 3.253 2.179–4.8568 <0.001
Hematologic malignancy 2.088 1.041–4.189 0.038
Chronic kidney disease 0.424 0.279–0.643 <0.001
Pneumonia 3.302 2.033–5.364 <0.001
Other infections 1.525 1.068–2.176 0.020
Postbleeding 2.569 1.680–3.928 <0.001
Acute myocardial infarction 1.337 0.645–2.772 0.435
Creatinine 7.561 2.142–26.686 0.002
Albumin 0.993 0.860–1.146 0.922
C-reactive protein 1.011 1.001–1.021 0.027
CI, conﬁdence interval.
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nonsurvivors in the present study. Among the causes of admis-
sion, programmed HD for CKD was more common in survivors,
whereas pneumonia, acute myocardial infarction, prior che-
motherapy, and prior bleeding were more common among
nonsurvivors. The frequencies of urinary tract infection and
postoperative AKI did not differ between survivors and nonsurvi-
vors. The higher in-hospital mortality rate in pneumonia patients
may be associated with ventilator use and ICU care.
A low serum albumin level is reported to be a predictor of
mortality in dialysis patients [8,14,15]. Hypoalbuminemia, an
indicator of malnutrition, is a powerful independent predictor of
mortality in patients on RRT [12,16,17]. Furthermore, serum
albumin is reported to be a predictor of hospitalization and
mortality [18,19]. Although serum albumin levels were lower
among nonsurvivors in the present study, this was not a
signiﬁcant risk factor for in-hospital mortality after adjusting
for other confounders. In-hospital mortality might be associated
with the acute stage; albumin's half-life is approximately 20
days, which may be too long present in the acute stage, such as
during CPR or acute myocardial infarction. Meanwhile, CRP and
leukocytosis were higher in nonsurvivors, suggesting in-hospital
mortality may be associated with infection.
An interesting ﬁnding of the present study is the seemingly
paradoxical association between diabetes and lower in-
hospital mortality, which has also been reported by Bradbury
et al [8]. A possible explanation for this ﬁnding is that patients
with diabetes mellitus are more likely to see a physician on a
regular basis than nondiabetic patients; therefore, they might
be better prepared for the transitional period of early dialysis
therapy and programmed HD, resulting in lower mortality.
A second reason might be that diabetic patients accounted for
a small proportion of AKI patients and a large proportion of
CKD patients, who received programmed HD.
Among clinical variables, the type of the vascular access
was strongly associated with mortality. Central venous
catheter insertion is strongly associated with mortality com-
pared with arteriovenous ﬁstula or arteriovenous graft in HD
patients [20–23]. In the present study, jugular catheter inser-
tion did not show different in-hospital mortality between
survivors and nonsurvivors. However, femoral catheterinsertion was more common in nonsurvivors, whereas tun-
neled cuffed jugular catheters, arteriovenous ﬁstula, and
arteriovenous graft were signiﬁcantly more common in survi-
vors. These ﬁndings are concordant with a previous report
indicating uncuffed catheters are associated with adverse
outcomes and are independent risk factors for hospitalization
compared with tunneled cuffed catheters [24].
The present study has several limitations. First, the study
population included not only CKD but also AKI patients. Thus,
the study population might be heterogeneous in terms of the
underlying diseases and related risk factors for kidney injury.
Second, the possibility of residual confounding factors due to
unmeasured confounders or measurement errors in the
included factors could not be excluded. Finally, as this was a
retrospective, single-center, observational study, it was not
possible to demonstrate a causal relationship between dialysis
initiation and in-hospital mortality.
In summary, incident HD patients had a high in-hospital
mortality rate. CPR, infections such as pneumonia, and the use
of inotropes and ventilators were strong risk factors for in-
hospital mortality in patients starting incident HD. Meanwhile,
elective HD for CKD reduced the risk of in-hospital mortality.Conﬂicts of interest
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